Just over a year ago, the U.S. FDA released detailed information about the restructuring of the newly realigned Office of Regulatory Affairs (ORA) (1). Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA, provided an update on this and other ORA initiatives on Sept. 24 in the second plenary of the 2018 PDA/FDA Joint Regulatory Conference.